Latest News and Press Releases
Want to stay updated on the latest news?
-
INDIANAPOLIS, IN., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Board-certified medical oncologists, M. Sarfraz Nawaz, MD and Ruemu E. Birhiray, MD from community oncology practice Hematology Oncology of...
-
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
-
Smart Immune to Present Details of Pioneering Clinical Study at the American Society of Hematology (ASH) Annual Meeting 2023 PARIS, France, 02 November 2023 – Smart Immune, a clinical-stage...
-
FORT MYERS, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce that seven research studies co-authored by AON physicians were presented at the...
-
Fort Myers, Florida, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Research conducted at Florida Cancer Specialists & Research Institute, LLC (FCS) that is contributing to global advancements in the...
-
SAN DIEGO, Nov. 03, 2022 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
-
CHICAGO, June 22, 2022 (GLOBE NEWSWIRE) -- American Society for Transplantation and Cellular Therapy (ASTCT) is pleased to announce that Owhofasa Agbedia, MD, MPH, has been selected by the American...
-
Fort Myers, Fla., Dec. 16, 2021 (GLOBE NEWSWIRE) -- American Oncology Network, LLC (AON) is pleased to announce that eight research studies co-authored by AON physicians were presented at the...
-
ExCellThera announces data to be presented at the American Society of Hematology 2021 annual meeting
MONTRÉAL, Nov. 29, 2021 (GLOBE NEWSWIRE) -- ExCellThera Inc., a clinical-stage cell expansion and engineering company delivering molecules and bioengineering solutions to expand and engineer...
-
Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease 2 out of 3 Patients at DL1 Achieved...